Technology Transfer opportunities from developed countries are significant openings for India to move into translational medicine much more quickly and produces products for the global market. This model will also help India develop its R & D infrastructure with the revenue that might come from the sale of the products. In the opinion of the Institute, there are numerous emerging opportunities for ‘licensing-in’ potential technologies from developed countries.

The Institute believes that patenting and licensing biomedical technologies facilitate and bring in Venture Capital (VP)-based domestic and Foreign Direct Investments (FDI) by commercial partners for further research and commercial development of new products that can penetrate global markets creating wealth for the country. This model has led to many successful products. With the explosion of start-up companies, ‘In–Licensing’ of early stage and matured biomedical technologies will place India in a highly competitive advantage in the global market while it builds its own IP portfolios. India’s success depends on the effective utilization of this opportunity in these highly dynamic and growing biomedical portfolios. Commercial positioning using an ‘In Licensing’ route should be critically viewed as an opportunity. However, there are many important legal, business, and scientific considerations that need be tackled carefully in developing successful licensing agreements.